Light-assisted small-molecule screening against protein kinases by Ingles-Prieto, Alvaro et al.
 
 
Ingles-Prieto et al. 1 
 
Light-assisted small molecule screening against 
protein kinases 
 
 
Álvaro Inglés-Prieto1, Eva Reichhart1, Markus K. Muellner2, Matthias Nowak1, Sebastian M. 
Nijman2,4, Michael Grusch3 & Harald Janovjak1,* 
 
 
1 Institute of Science and Technology Austria (IST Austria), 3400 Klosterneuburg, Austria. 
2 CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, 
1090 Vienna, Austria. 
3 Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center Vienna, 
Medical University of Vienna, 1090 Vienna, Austria. 
 
 
 
 
 
 
 
4 Present address: Ludwig Institute for Cancer Research, NDM Research Building, Roosevelt Drive, 
Headington, Oxford OX3 7XR, United Kingdom. 
* e-mail: harald@ist.ac.at 
  
 
 
Ingles-Prieto et al. 2 
 
Abstract 
High-throughput live-cell screens are intricate elements of systems biology studies and drug 
discovery pipelines. Here, we demonstrate an optogenetics-assisted method that obviates the 
addition of chemical activators and reporters, reduces the number of operational steps and 
increases information content in a cell-based small molecule screen against human protein kinases 
including an orphan receptor tyrosine kinase. This blueprint for all-optical screening can be adapted 
to many drug targets and cellular processes. 
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Main text 
Over the past decades, many chemical processes have been improved by replacing additives, such 
as catalysts, initiators or emulsifiers, with physical stimuli, such as light or ultrasound1-4. Although 
replacement results in reduced cost, increased robustness and improved sustainability, this general 
principle has not found many adaptations in chemical biology. Automated screens using living cells 
are essential in the identification and characterization of small molecules that act on disease-related 
proteins and cellular pathways. However, in many cell-based screens the need to add reagents that 
alter or report on cell activity results in complex operational design, high cost and sources of error. 
Furthermore, mammalian cells are sensitive to environmental perturbations (e.g. temperature or 
ionic strength) and subject to inherent variability. In neurobiology and cell biology, optogenetics and 
photopharmacology have recently harnessed the power of light to manipulate the behavior of cells 
and animals non-invasively and with high spatial and temporal precision5-7. Here, we developed an 
optogenetics-assisted, cell-based screening method that interrogates receptor tyrosine kinases 
(RTKs) and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) 
pathway comprising one G-protein (Ras) and three intracellular kinases (Raf, MEK and ERK). We 
demonstrate that in this screening method the use of light for activation and detection of cell 
signaling obviated the need for addition of reagents, limited the number of operational steps and 
provided new strategies to increase specificity and counter variability. 
The MAPK/ERK pathway is activated by RTKs and regulates cell survival, proliferation and 
differentiation. Modulators of the MAPK/ERK pathway, RTKs and other protein kinases are pursued 
as new therapeutics in cancer and metabolic and neurodegenerative disorders. We first engineered 
human embryonic kidney 293 (HEK293) cells that contain light-activated RTKs and a genetic 
fluorescent MAPK/ERK pathway reporter (Fig. 1a). The light-activated RTKs (also called ‘Opto-
RTKs’) are modified growth factor receptors that are insensitive to their natural ligands but activated 
by blue light-induced homodimerization through incorporation of the light-oxygen-voltage-sensing 
(LOV) domain of aureochrome1 from V. frigida8 (Supplementary Results, Supplementary Fig. 1). 
We initially employed two Opto-RTKs, the light-activated murine fibroblast growth factor receptor 1 
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(Opto-mFGFR1) and the light-activated human epidermal growth factor receptor (Opto-hEGFR). In 
the fluorescent reporter (SRE-GFP), tandem repeats of serum response element (SRE)9, an 
enhancer sequence responsive to signaling pathways including the MAPK/ERK pathway, precede a 
gene coding for the green fluorescent protein (GFP). The engineered cells respond to light at a 
wavelength and intensity suited for Opto-RTK activation (~470 nm, intensity200 µW/cm2) with 
increased production of GFP (Fig. 1b and Supplementary Fig. 2), and combining Opto-RTKs and 
GFP reporter thus enables a novel ‘all-optical’ mode of operation where light was used to activate 
as well as read cellular signaling. Using this mode of operation, we were able to screen small 
molecules in the 384-well plate format without addition of reagents to induce or detect pathway 
activation and with few handling steps (Fig. 1c and Supplementary Fig. 3). This assay was robust 
(Z’-factor ≥ 0.7, Materials and Methods) and not influenced by ambient light (Supplementary Fig. 
4) or bleaching (Supplementary Fig. 5). In addition, all wells in the 384-well plate were activated at 
the same time and with nearly identical intensity using light emitting diodes (LEDs) (deviation of 
intensity <0.05% over the plate, day-to-day variability <0.05%). In a set of kinase inhibitors 
(Supplementary Table 1), three molecules inhibited the mFGFR1-MAPK/ERK-axis by >50%, and 
these molecules are known kinase inhibitors of FGFR1 or of MAPK/ERK pathway components (Fig. 
1c, d and Supplementary Fig. 6). To demonstrate the ability to identify whether ligands act at the 
receptor or downstream pathway, we conducted the same screen with Opto-hEGFR. Unlike FGFR1, 
which couples to the MAPK/ERK pathway via additional FGFR substrate adaptor proteins, EGFR 
directly activates it. Three molecules inhibited the EGFR1-MAPK/ERK-axis, and these molecules 
are known kinase inhibitors of EGFR or pathway components (Fig. 1d). Because inhibitors of 
FGFR1 were not detected in the screen with EGFR and vice versa, the method selectively identified 
those small molecules that specifically act on receptors or common downstream proteins. 
Collectively, these results demonstrate a cell-based small molecule screen in the 384-well format 
assisted by optogenetics. The method functions without added reagents and a reduced number of 
operational steps as physical contact to the living cells was not required. 
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Because peptides or other agonists are not required, the all-optical method can also screen 
against ‘orphan’ receptors, i.e. receptors for which native ligands are not known. To demonstrate 
optical control of an orphan receptor, we first identified human orphan RTKs through de novo 
database and bioinformatics analysis (Supplementary Fig. 7). The database search reported 
human ROS1 (hROS1), a proto-oncogene orphan RTK that is activated by protein fusion in a 
variety of tumor cell types10, 11. To engineer a light-activated variant of human hROS1 (Opto-
hROS1), we fused the dimerizing LOV domain to the intracellular domain of hROS1 
(Supplementary Fig. 8). When testing the kinase inhibitor library against Opto-hROS1, we found 
three molecules that inhibited the hROS1-MAPK/ERK-axis (Supplementary Fig. 9). Two of these 
molecules (crizotinib and GSK-1120212) are known kinase inhibitors of hROS1 and pathway 
components. The third molecule (AV-95112) was active specifically against hROS1 but not mFGFR1 
or hEGFR (Supplementary Fig. 10). Notably, AV-951 was previously not assigned to inhibit 
hROS1. 
We next extended the method to increase information content in cell-based screens. First, 
we demonstrate that a second, spectrally-distinct FP (e.g. mKate213) can be incorporated and 
detected separately from GFP (Supplementary Fig. 10). If expressed constitutively, this second 
protein can report small molecules that inhibit gene transcription and protein translation/folding14, 
potential assay confounders. As GFP exhibits fluorescence in the same wavelength range as many 
small molecules in screening collections, a red FP may generally improve assay performance. 
Second, we tested whether the ability to spatially focus activation can improve the method. 
Stimulation of optogenetic tools is often realized using custom-built hardware and continuous 
illumination15-17. However, microplate readers commonly part of screening platforms employ 
discontinuous flash lamps. We thus tested if flashes provide sufficient intensity to activate 
optogenetic proteins and found that 900 blue light flashes (2 s duration, 9 W average power of 
lamp) resulted in robust MAPK/ERK pathway activation in SPC212 cells expressing Opto-mFGFR1 
(Fig. 2a to c). Using a light guide-lens assembly, we then confined flash lamp stimulation to the 
center of single wells (area3.14 mm2) while leaving the well periphery unstimulated (Fig. 2d, e). 
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We thereby created two cell populations (activated center population and silent peripheral 
population) within each well, and we exploited these populations to obtain high-content 
measurements. When testing small molecules, we found that inactive molecules left centers 
activated and peripheries silent, inhibitory molecules resulted in silent centers and silent peripheries, 
and activators resulted in activated centers and activated peripheries (Fig. 2f). This result showed 
that probing two cell populations in a single well was sufficient to test for inhibitory or activating 
effects of a small molecule. In further experiments, one cell population may also serve as a local 
control for others. Because trial and control are performed under identical conditions in the same 
well, the influence of environmental perturbations on measurement outcome may be reduced. 
These experiments can be directly transferred to high-throughput platform microplate readers 
without the need for specialized instrumentation. 
In summary, we demonstrate that incorporation of optogenetics enabled cell-based small 
molecule screens without additives but minimal operational steps and increased information 
content. Light acted as a universal ligand for receptors of different families (e.g. FGFR1, EGFR or 
ROS1), but, at the same time, was specific to stimulate the genetically-engineered receptors. 
Interference from endogenous receptors that may be also activated by added ligands can be 
excluded, which is particularly desirable when targeting receptors for which specific ligands are not 
available. For instance, in our experiments EGF or FGF2 will have bound to several receptor 
proteins expressed in these cells (FGFR1, FGFR2, FGFR3, FGFR-like 1 and EGFR), while Opto-
RTK activation was specific to the engineered receptor. Activation by light may be in in real-time to 
reveal new insights into molecular inhibition and cellular signaling mechanisms. For instance, the 
interaction between small molecules and proteins can be activation-state dependent18, 19, and the 
duration and frequency of activation can determine choice of pathway or functional outcome20, 21. 
The ability to switch signals on with temporal precision and tunable strength, even within one well, 
may explore these phenomena in a systematic and automated manner. This may be of particular 
use when exploring ‘mutagenesis space’ in genetic libraries and the method is compatible with 
transient cell transfection. We further foresee the extension and adaptation of this approach to other 
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drug targets to be straightforward because of an increasing number of available optogenetic tools 
and fluorescent reporters. 
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Figure legends for main text 
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Figure 1. All-optical screen against RTKs and the MAPK/ERK pathway. 
(a) HEK293 cells were engineered to contain an Opto-RTK (Opto-mFGFR1, Opto-hEGFR or Opto-
hROS1, Supplementary Fig. 1 and Supplementary Fig. 8) and a MAPK/ERK pathway-responsive 
GFP reporter (SRE-GFP). In all-optical screening, effects of small molecules (e.g. receptor inhibitors 
or pathway inhibitors) are tested in 384-well plates by first activating the RTK with blue light (470 
nm, I200 µW/cm2) followed by detection of pathway activity using the GFP reporter. In cells treated 
with inhibitors of RTKs or of components of the MAPK/ERK pathway, GFP expression will be 
absent. Except for small molecule addition, the process does not require contact to the cells, 
solution exchange or added reagents (Supplementary Fig. 3). (b) Control experiments 
demonstrating activation of MAPK/ERK pathway by Opto-mFGFR1 and blue light as measured 
using the GFP reporter. Mean raw fluorescent units (RFU) (one representative experiment 
performed in triplicate) are shown. (c) All-optical screen against mFGFR1 and MAPK/ERK pathway 
(68 small molecules, final concentration 5 nM). PD-166866 (final concentration 5 M), a specific 
FGFR1 inhibitor, and DMSO were used as controls (red and green bars). Mean percent of control 
(POC) values (two independent experiments performed in duplicate) are shown. (d) Comparison of 
all-optical experiments with Opto-mFGFR1 (black bars) and Opto-hEGFR (grey bars) allow 
identifying small molecules that specifically inhibit mFGFR1 (ponatinib, PD-173074), hEGFR (CI-
1033, AV-412, gefitinib) or downstream proteins of the MAPK/ERK pathway (GSK-1120212). Mean 
POC values (two independent experiments performed in duplicate) are shown. 
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Figure 2. Optogenetics-enabled, internally-referenced measurement of MAPK/ERK pathway. 
(a) Whole well (I.) or spatially-confined (II.) light stimulation (=470  5 nm) of SPC212Opto-mFGFR1 
cells was performed in a microplate reader. 48-well plates were chosen for these experiments to 
enable visual evaluation after anti-pERK1/2 immunohistochemistry (see b and d). (b) Raw data 
photographs of cells stimulated with EGF (5.5 ng/ml) or light (distributed over the well in a 33 
matrix). MAPK/ERK pathway was activated by EGF in SPC212 cells or light in SPC212Opto-mFGFR1 
cells but not in controls. (c) Quantification of b. Mean (normalized) absorption values (one 
representative experiment with nine positions) are shown. (d) Raw data photographs of local 
activation (area3.14 mm2) of the MAPK/ERK pathway by spatially-confined illumination of 
SPC212Opto-mFGFR1 cells. Activation is limited to the center of the well and inhibited by PD-166866 
(final concentration 5 µM). (e) Quantification of d. (f) Characterization of an inactive molecule 
(vehicle, left bars), inhibitor (PD-166866, middle bars) or activator (EGF, right bars) through internal 
references in a single measurement. Mean (normalized) absorption values (two independent 
experiments performed in triplicate or duplicate) are shown. Scale bar in b and c is 1 mm. 
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Online Methods 
 
Kinase inhibitor library 
Small molecules are listed in Supplementary Table 1. Out of the tested 68 small molecules, 62 
molecules target protein kinases. 
 
Gene constructs 
Opto-mFGFR1 and Opto-hEGFR in pcDNA3.1(-) (Life Technologies) were described previously8. 
Identification of ROS1 and genetic engineering of Opto-hROS1 is described below. The SRE-GFP 
reporter vector and the vector containing MonsterGFP under the control of the CMV promoter were 
obtained from Qiagen/SA Biosciences. mKate2 was obtained from D.M. Chudakov (Shemiakin-
Ovchinnikov Institute of Bioorganic Chemistry)/Evrogen13 and subcloned into pcDNA3.1(-) using 
polymerase chain reaction. 
 
Cell culture and transfection 
Malignant pleural mesothelioma SPC212 cells were kindly provided by R. Stahel (University of 
Zurich) and HEK293 were derived by F.L. Graham (McMaster University). Malignant pleural 
mesothelioma SPC212 cells stably expressing Opto-mFGFR18 and HEK293 cells were maintained 
in RPMI1640 and DMEM, resp., in a humidified incubator with 5% CO2 atmosphere. Media were 
supplemented with 10% FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin, and RPMI1640 was 
additionally supplemented with 2 mM L-Glutamine. For transfection of HEK293 cells, 2106 cells 
were seeded in 60 mm cell culture dishes coated with poly-L-ornithine (PLO, Sigma). Cells were 
transfected with 4.04 to 8.04 µg total DNA per dish (receptor, pcDNA3.1(-) empty vector, and 
reporter at a ratio of 1:50:50 or 1:100:100) using polyethylenimine (Polysciences). For mock 
transfected cells (Fig. 1b and Supplementary Fig. 2, “HEK293”), receptor vector was omitted in the 
transfection mixture. For experiments with mKate213 (Supplementary Fig. 11), empty vector was 
substituted by mKate2 in pcDNA3.1(-). For control experiments with MonsterGFP (Supplementary 
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Fig. 5), reporter vector and receptor vector was substituted by vector containing MonsterGFP under 
the control of the CMV promoter.  
 
Custom incubator for light stimulation of well plates 
A thermoelectric incubator (PT2499, ExoTerra) was equipped with 300 RGB LEDs (5050SMD, max 
 630 nm (red light), max  530 nm (green light), max  470 nm (blue light), bandwidth   5 nm). 
Light intensity was controlled with a dimmer and measured with a digital power meter (PM120VA, 
Thorlabs). Blue light intensity at maximal output was 247 W/cm2. Light of this intensity is sufficient 
for activation and well tolerated by mammalian cells without signs of toxicity even for extended 
periods of time. Hardware to maintain a CO2 atmosphere is not required if medium supplemented 
with HEPES (25 mM) is used during light stimulation (see below). To measure profile of light 
distribution, the sensor of the power meter was mounted on a holder and moved in 1 cm steps. 
Intensity was recorded and deviation between highest and lowest intensity was calculated (<0.13 
W/cm2). Day-to-day variability of light was measured in the same way but on several days 
distributed over one week (<0.13 W/cm2). For evaluation of the effect of ambient light 
(Supplementary Fig. 4), cells were stimulated immediately after seeding with white light of 
comparable intensity to that encountered in a dim room. 
 
All-optical drug screening against RTKs and the MAPK/ERK pathway 
The workflow is depicted in Supplementary Fig. 3. Transfected HEK293 cells were kept in DMEM 
(supplemented with 5% FBS and no antibiotics; “D5-AB” medium) for 6 h. Afterwards, 5’000 to 
20’000 cells were seeded in each well of 384-well plates (3712, Corning) in low-fluorescence 
medium (FlouroBrite™, Life Technologies, supplemented with 25 mM HEPES, 0.5% FBS, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin, pH 7.5; “COI” medium). Small molecules were added and 
after 1 h cells were stimulated with blue light in a custom incubator (see above). Unstimulated cells 
were kept in the dark by covering selected wells on the same 384-well plate. GFP fluorescence was 
then measured in a microplate reader (Synergy H1, BioTek) at the optimized excitation wavelength 
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of 500  5 nm and emission wavelength of 535  5 nm (10 measurements per well, measurement 
duration: 10 ms, gain: 90 to 130). We found that 384-well plates exhibit fluorescence in the blue-
green part of the light spectrum (Supplementary Fig. 11), and optimization of the excitation 
wavelength allowed for improved signal to noise ratio. mKate2 fluorescence was measured at 
excitation wavelength of 570  5 nm and emission wavelength of 660  5 nm. 
 
Identification of Orphan RTKs 
Orphan RTKs were identified using the bioinformatics procedure described in Supplementary Fig. 
7. Protein family search with the PFAM motif “Pkinase_Tyr” (PF07714) at the Wellcome Trust 
Sanger Institute (http://pfam.xfam.org/)22 retrieved a comprehensive list of human Tyr kinases. This 
PFAM motif is a good representative of kinase domains found in RTKs (we confirmed that it is found 
in members of diverse RTK families, such as fibroblast growth factor receptors, ErbB receptors, 
Insulin-like growth factor receptor, neurotrophin receptors, ROR receptors). Retrieval of these 
sequences was followed by transmembrane helix prediction with TMHMM23 to retain only 
sequences with transmembrane helices. To remove sequence redundancy and assign sequence 
fragments clustering with UCLUST24 was performed. 69 clusters with a unique candidate sequence 
each for RTKs were obtained Supplementary Table 2 and orphan RTKs were identified by manual 
curation. 
 
Genetic engineering of Opto-ROS1 
A sequence coding for the ROS1 gene was obtained from the Mammalian Gene Collection 
(Dharmacon, GE Life Science). Using inverse PCR, an expression vector was prepared starting 
from an Opto-mFGFR1 vector in which the mFGFR1 ICD was replaced by two inverted SapI 
restriction sites. The ROS1 ICD was amplified with oligonucleotides (F: GAT CGC TCT TCA GAC 
CAT AGA AGA TTA AAG AAT CAA AAA AG, R: GAT CGC TCT TCC AGG ATC AGA CCC ATC 
TCC ATA TCC ACT G) and PCR and inserted into the vector using ‘Golden Gate’ cloning25. 
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Activation of Opto-RTKs in microplate reader and ERK1/2 phosphorylation 
5104 cells per well were seeded in 48-well plates coated with PLO and starved for 24 h in medium 
containing 0.1% FBS. Small molecules or EGF (5.5 ng/ml) were added to the cells one h prior to 
onset of light stimulation. A microplate reader equipped with monochromators (Synergy H1, BioTek; 
9 W average power of flash lamp, 2 s flash duration) was repurposed for spatially-confined light 
stimulation and read-out. For stimulating entire wells, the device’s area scanning mode was 
configured for a 33 matrix with horizontal and vertical point spacing of 2 mm. This protocol was 
repeated 100 times. For stimulating well centers, the device’s area scanning mode was configured 
for a 99 matrix with minimal point spacing. This protocol was repeated three times. In both 
protocols, bottom illumination at an excitation wavelength of 470 nm was applied. Cells were then 
fixed and permeabilised in a solution containing 4% formaldehyde and 1% methanol for 15 min. 
After washing with PBS three times for 5 min, cells were blocked in 1% BSA, 0.1% Tween in PBS 
for 30 min and incubated with anti-pERK1/2 (#9101, Cell Signaling Technology, 1:500) for 1 h. After 
washing with PBS three times for 5 min, signal was developed using the UltraVision LP detection 
system (Thermo Scientific) and 3,30-diaminobenzidine as chromogen. For read-out, the device’s 
area scanning mode was configured for a 33 with spacing of 3 mm. In some experiments, this 
protocol was repeated three times with absorbance measurements at 450 nm. Data were 
normalized to EGF-treated wells and background (SPC212 cells in the dark) was subtracted. 
Photographs were acquired with a macroscope26. This approach can also be used for blue light 
activation of gene transcription using a different optogenetic system (see below). 
 
Optimization of excitation wavelength for microplate reader GFP measurements 
The microplate reader was used to quantify fluorescence of 384-well plates filled with low-
fluorescence media. Emission spectra were acquired at several fixed excitation wavelengths 
(Supplementary Fig. 12). 
 
  
 
 
Ingles-Prieto et al. 19 
 
Assay validation and statistical analysis 
Z’ factors (Supplementary Table 3) were calculated for interleaved-signal format plates following 
ܼᇱ݂ܽܿݐ݋ݎ ൌ 1 െ	3 ൈ ሺݏݐ݀	ሺܿାሻ ൅ ݏݐ݀	ሺܿିሻሻ|ܽݒ݃ሺܿାሻ െ ܽݒ݃ሺܿିሻ|  
where ݏݐ݀	ሺܿାሻ and ܽݒ݃ሺܿାሻ are the standard deviation and the average of DMSO treated samples, 
resp., and ݏݐ݀	ሺܿିሻ and ܽݒ݃ሺܿିሻ are the standard deviation and the average of PD-166866 (INH; 
final concentration 20M) treated samples, resp. On each plate, ten columns of DMSO treated 
samples and ten columns of INH treated samples were tested in groups of two and in alternating 
order). Z’ factors for these plates were ≥0.70 (Supplementary Table 3) and failures were not 
observed. Percentage of control (POC) values were calculated following: 
ܱܲܥ ൌ ௜ܺܽݒ݃ሺܿାሻ 	ൈ 	100 
where ௜ܺ is the measurement of the ith small molecule and avg(c+) is the average measurement of 
the DMSO treated samples. 
  
 
 
Ingles-Prieto et al. 20 
 
Methods-only References 
 
22. Finn, R.D. et al. Nucleic Acids Res. 38, D211-222 (2010). 
23. Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E.L. J. Mol. Biol. 305, 567-580 
(2001). 
24. Edgar, R.C. Bioinformatics 26, 2460-2461 (2010). 
25. Engler, C. & Marillonnet, S. Methods Mol Biol 1116, 119-131 (2014). 
26. Chait, R., Shrestha, S., Shah, A.K., Michel, J.B. & Kishony, R. PLoS One 5, e15179 (2010). 
 
  
 
Ingles-Prieto et al. 1 
 
SUPPLEMENTARY INFORMATION 
 
Light-assisted small molecule screening against 
protein kinases 
 
 
Álvaro Inglés-Prieto1, Eva Reichhart1, Markus K. Muellner2, Sebastian M. Nijman2,4, Michael 
Grusch3 & Harald Janovjak1,* 
 
1 Institute of Science and Technology Austria (IST Austria), 3400 Klosterneuburg, Austria. 
2 CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, 
1090 Vienna, Austria. 
3 Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center Vienna, 
Medical University of Vienna, 1090 Vienna, Austria. 
 
 
 
 
 
 
 
4 Present address: Ludwig Institute for Cancer Research, NDM Research Building, Roosevelt Drive, 
Headington, Oxford OX3 7XR, United Kingdom. 
*e-mail: harald@ist.ac.at 
  
  
 
Ingles-Prieto et al. 2 
 
Supplementary Results 
 
 
 
 
Supplementary Figure 1: Design and function of Opto-RTKs. RTKs consist of an extracellular 
ligand-binding domain (LBD), single-span transmembrane domain (TMD) and intracellular domain 
(ICD), which includes the kinase domain (KD) and a C-terminal tail domain (CTD). In Opto-RTKs 
(e.g. Opto-mFGFR1 or Opto-hEGFR1), only the ICD is retained to render the protein insensitive to 
endogenous ligands. The ICD is attached to the membrane using a myristoylation domain (MYR; for 
mFGFR1) or the extracellular and transmembrane domain of the p75 low-affinity neurotrophin 
receptor (p75; for hEGFR). The light-oxygen-voltage-sensing (LOV) domain from aureochrome1 of 
the algae Vaucheria frigida is incorporated at the ICD C-terminus and induces homodimerization 
upon blue light stimulation. Except for MYR and p75, domains are drawn to scale (length of amino 
acid sequences). 
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Supplementary Figure 2: Activation of MAPK/ERK pathway by Opto-hEGFR. Activation was 
measured using SRE-GFP after 18 h and is represented as raw fluorescence units (RFU). Mean 
values (two independent experiments performed in duplicate) are shown. 
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Supplementary Figure 3: Workflow of the all-optical screen method (compare to Fig. 1). 
*Transfection can be omitted when a stable cell line is used. **Drug addition can be performed at 
the beginning of the workflow by preparing drugs in the 384-well plates. Media are described in 
Materials and Methods. 
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Supplementary Figure 4: Opto-RTK activation by room light. HEK293 cells transfected with 
Opto-mFGFR1 and SRE-GFP were exposed to dimmed white laboratory light (intensity 30 
W/cm2). To analyze MAPK/ERK pathway activation, fluorescence was measured every hour. An 
increase in reporter signal is detected for illumination duration exceeding 4 h. Mean raw 
fluorescence units (RFU) (one representative experiment performed in eight wells) are shown. 
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Supplementary Figure 5: Bleaching of GFP by stimulation light. MonsterGFP, which is the 
fluorescent protein employed in the reporter plasmid, was expressed in HEK293 cells under the 
control of the constitutively active CMV promoter. Cells were stimulated with light following the 
standard protocol (Fig. 1 and Supplementary Fig. 3) to test if stimulation light bleaches GFP. 
Bleaching <10% was detected. Mean raw fluorescence units (RFU) (one representative experiment 
performed in 96 wells) are shown. 
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Supplementary Figure 6: Inhibition by FR180204 (F), sorafenib (S), and gefitinib (G) (final 
concentration 10 M). Mean raw fluorescence units (RFU) ± SEM (three independent experiments 
performed in duplicate) are shown. 
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Supplementary Figure 7: Bioinformatics procedure for identification of orphan RTKs. 
Individual steps are described in the Materials and Methods section. Databased search was 
conducted June 2014. 
  
 
Retrieve comprehensive inventory of human tyrosine kinases 
Database: Protein Family Database 
Source: http://pfam.xfam.org/ REF 2 
Filter: Must contain PF07714 
Result: 1486 protein sequences 
 
 
 
Limit to those sequences that contain predicted membrane 
helices 
Algorithm: TMHMM 2.0 (batch analysis) 
Source: www.cbs.dtu.dk/services/TMHMM/ REF 3 
Filter: predhel>0 
Result: 705 protein sequences 
 
 
 
Remove duplicates and sequence fragments 
Algorithm: UCLUST 3.0.617 
Source: http://drive5.com/usearch/ REF 4 
Filter: 90% sequence identity 
Result: 69 sequence clusters with one unique seed sequence each 
(see Supplementary Table 2) 
 
 
 
Identify orphan RTKs 
Manual inspection of seed sequences and literature search (see main 
text) 
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Supplementary Figure 8: Light activation of an orphan RTK. (a) The orphan RTK hROS1 was 
re-engineered to be activated by light by fusing its cytosolic domain to the dimerizing LOV domain. 
Except for ECD of hROS1, domains are drawn to scale (length of amino acid sequences). (b) 
Control experiments demonstrating activation of MAPK/ERK pathway by Opto-hROS1 and specific 
inhibition by crizotinib (C; final concentration 100 nM). Mean raw fluorescence units (RFU) (one 
representative experiment performed in triplicate) are shown. 
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Supplementary Figure 9: All-optical screen against hROS1 and MAPK/ERK pathway. The 
screen contained the same 68 small molecules as in Fig. 1 (final concentration 100 nM). GSK-
1120212 (final concentration 1 M) and DMSO were used as controls (red and green bars). Mean 
percent of control (POC) values (two independent experiments performed in duplicate) are shown. 
  
  
 
Ingles-Prieto et al. 11 
 
 
 
 
Supplementary Figure 10: Inhibition of the hROS1-MAPK/ERK-axis (squares), mFGFR1-
MAPK/ERK-axis (triangles) and EGFR-MAPK/ERK-axis (spheres) by increasing doses of AV-
951. Mean normalized (to datapoint with the highest intensity in each experiment) fluorescence 
units (FU) (two independent experiments performed in eight wells each) are shown. 
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Supplementary Figure 11: Simultaneous measurement of disruption of transcription and 
translation. The red fluorescent protein mKate2 extends all-optical experiments with a 
measurement of disruption of transcription and translation. mKate2, SRE-GFP and Opto-mFGFR1 
were co-expressed in HEK293 cells and stimulated with light as described for Fig. 1. Expression of 
mKate2 was under the control of the constitutively active CMV promoter and is thus mainly sensitive 
to disruption of transcription and translation. Incubation with PD-166866 indicates reduced MAPK 
activity specifically and demonstrates that the two fluorescent proteins can be detected separately. 
Mean normalized (to measurements without inhibitor) fluorescence units (FU) (two independent 
experiments performed in duplicate) are shown. 
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Supplementary Figure 12: Background fluorescence of 384-well plates filled with COI 
medium. Fluorescence emission spectra of single wells filled with low-fluorescence media were 
recorded for four excitation wavelengths between 470 and 500 nm (± 5). Excitation wavelength of 
500±5 nm was selected for experiments because of the low background fluorescence (one 
representative experiment). 
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Supplementary Table 1: Small molecules used in this manuscript along with POC inhibition 
of the mFGFR1-MAPK/ERK-axis. 
Small molecule Canonical target(s) Source POC (Fig. 1c) 
R-406 Syk MedChem Express 85 
GDC-0941 PI3Kα/δ Selleck 82 
GSK-1120212 MEK1/2 Selleck 4 
Sunitinib VEGFR2, PDGFRβ, c-Kit Synthesis 86 
Imatinib v-Abl, c-Kit, PDGFR Selleck 94 
Erlotinib EGFR Synthesis 94 
Vargatef VEGFR1/2/3, FGFR1/2/3, PDGFRα/β Synthesis 75 
CI-1033 EGFR, ErbB2 Selleck 80 
MP-470 c-Kit, PDGFRα, Flt3 Selleck 83 
Flavopiridol CDK1/2/4/6, EGFR, PKA Santa Cruz 92 
Ponatinib Abl, PDGFRα, VEGFR2, FGFR1, Src ARIAD 13 
AT-9283 JAK2/3 Selleck 80 
Paclitaxel Microtubule polymer stabilizer Sigma 85 
SR-3677 ROCK2 Sigma 85 
BX-795 PDK1 Selleck 89 
SB-202190 p38α/β  Selleck 90 
BX-912 PDK1 Selleck 89 
Purvalanol B CDC2, CDK2/4/5 Tocris 101 
AG-13958 VEGF Synkinase 67 
Ki-20227 c-Fms, VEGFR2, PDGFRβ, c-Kit APExBio 86 
Crizotinib c-Met, ALK  APExBio 81 
Masatinib Abl, Src, c-Kit, Synthesis 81 
Sorafenib Raf-1, B-Raf, VEGFR-2 Synthesis 86 
Lapatinib EGFR, ErbB2 Synthesis 81 
CYT11387 JAK1/2 Synthesis 88 
Temsirolimus mTOR Selleck 79 
Bosutinib Src, Abl Synthesis 94 
CP-724714 ErbB2 Selleck 90 
AMG-Tie2-1 Tie-2 Synkinase 63 
TAK-715 p38α  Selleck 82 
LDE225 SMO Selleck 90 
SB-590885 B-Raf APExBio 91 
TG-101209 JAK2, Flt3, RET Selleck 84 
Rho-15 ROCK1/2 Synthesis 83 
Dasatinib Abl, Src, c-Kit Synthesis 89 
Gefitinib EGFR Synthesis 83 
Mosetanib VEGFR1/2/3 Synthesis 90 
TGX-221 p110β Selleck 91 
Sanguinarine Na+/K+-and Mg2+-ATPase inhibitor Santa Cruz 83 
LDN-57444 Proteasome inhibitor for Uch-L1 Selleck 96 
PF-477736 Chk1, VEGFR2, Aurora-A, FGFR3, Flt3, Fms, 
Ret, Yes 
Sigma 80 
Lenvatinib VEGFR2/3/1, FGFR1, PDGFRα/β Source 72 
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FR180204 ERK1/2 MedChem Express 84 
KU-0063794 mTORC1/2 Selleck 92 
Nilotinib Bcr-Abl Selleck 95 
JNJ-7706621 CDK1/2, Aurora A/B Synthesis 83 
PF-62271 FAK, Pyk2 Selleck 81 
GW-441756 TrkA Synthesis 92 
Oligomycin ATP synthase Synthesis 84 
GSK-269962 ROCK1/2 Selleck 80 
ER-27319 Syk Selleck 81 
Vandetanib VEGFR2 Santa Cruz 75 
Enzastaurin PKCβ/α/γ/ε ARIAD 73 
Rapamycin mTOR Selleck 89 
PD-04217903 c-Met Sigma 101 
AT-7519 CDK1/2/4/6/9 Sigma 84 
RWJ-67657 p38α/β Selleck 77 
TG-101348 JAK2/1/3, BRD4 Selleck 79 
GSK-690693 Akt1/2/3, PKA, PrkX, PKC Selleck 69 
Bay 11-7082 NF-κB, IκBα  Tocris 69 
PD-173074 FGFR1 Synkinase 9 
Tandutinib FLT3, PDGFR, c-Kit APExBio 61 
ABT-737 Bcl-xL, Bcl-2, Bcl-w APExBio 55 
AV-951 VEGFR1/2/3, PDGFR, c-Kit Synthesis 63 
BMS-2 c-Met Synthesis 62 
AV-412 EGFR, ErbB2 Synthesis 72 
ZSTK-474 PI3Kδ Synthesis 66 
PD-166866 FGFR1 Selleck 3 
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Supplementary Table 2: Seed sequences retrieved using the bioinformatics procedure 
described in Supplementary Fig. 8. Where necessary for clarity, gene short names were added in 
square brackets to the Uniprot description column. Stars (*) denote RTKs identified as orphans. 
Uniprot-ID Uniprot Description 
D7RF68 AGTRAP-BRAF fusion protein 
Q59HE0 Colony stimulating factor 1 receptor variant 
Q6P4R6 EPH receptor A3 
Q7Z635 EPH receptor B4 
B7ZKW7 EPHA5 protein 
Q4LE53 EPHB2 variant protein 
P21709 Ephrin type-A receptor 1 
E7EML7 Ephrin type-A receptor 10 
P29317 Ephrin type-A receptor 2 
P54764 Ephrin type-A receptor 4 
Q9UF33 Ephrin type-A receptor 6 
D6RAL5 Ephrin type-A receptor 6 
P29322 Ephrin type-A receptor 8 
P54762 Ephrin type-B receptor 1 
P29323 Ephrin type-B receptor 2 
P54753 Ephrin type-B receptor 3 
O15197 Ephrin type-B receptor 6 
A2ABM8 Epithelial discoidin domain-containing receptor 1 
E7EU09 Fibroblast growth factor receptor [FGFR1] 
D3DRD5 Fibroblast growth factor receptor [FGFR2] 
F8W9L4 Fibroblast growth factor receptor [FGFR3] 
P22607 Fibroblast growth factor receptor 3 
Q59F30 Fibroblast growth factor receptor 4 variant 
P25092 Heat-stable enterotoxin receptor 
P08581 Hepatocyte growth factor receptor 
B2RE75 Highly similar to Homo sapiens c-mer proto-oncogene tyrosine kinase (MERTK) 
A8K2T7 Highly similar to Homo sapiens epidermal growth factor receptor (erythroblastic leukemia 
viral (v-erb-b) oncogene homolog avian) (EGFR) 
A8KAM8 Highly similar to Homo sapiens platelet-derived growth factor receptor betapolypeptide 
(PDGFRB) 
E9PFZ5 Inactive tyrosine-protein kinase 7 
P06213 Insulin receptor 
P14616 Insulin receptor-related protein 
P08069 Insulin-like growth factor 1 receptor 
Q59EB0 Kinase insert domain receptor (A type III receptor tyrosine kinase) variant [VEGFR2] 
P29376 Leukocyte tyrosine kinase receptor 
P07333 Macrophage colony-stimulating factor 1 receptor 
Q04912 Macrophage-stimulating protein receptor 
P10721 Maststem cell growth factor receptor Kit 
F5H3K9 Muscle skeletal receptor tyrosine-protein kinase 
Q16288 NT-3 growth factor receptor 
P16234 Platelet-derived growth factor receptor alpha 
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Q9H5K3* Protein kinase-like protein SgK196 
P08922* Proto-oncogene tyrosine-protein kinase ROS 
Q6MZT2 Putative uncharacterized protein DKFZp686D1354 [DDR2] 
A1L4F5 Receptor tyrosine kinase-like orphan receptor 2 [ROR2] 
P04626 Receptor tyrosine-protein kinase erbB-2 
P21860 Receptor tyrosine-protein kinase erbB-3 
Q15303 Receptor tyrosine-protein kinase erbB-4 
Q5VTU6 Receptor-type tyrosine-protein kinase FLT3 
F8TLW0 Ret proto-oncogene tyrosine-protein kinase receptor isoform a 
Q02846 Retinal guanylyl cyclase 1 
P51841 Retinal guanylyl cyclase 2 
Q8IWU2 Serinethreonine-protein kinase LMTK2 
Q96Q04 Serinethreonine-protein kinase LMTK3 
Q59HG2 TEK tyrosine kinase variant 
Q59FM9 TYRO3 protein tyrosine kinase variant 
Q15516 Tyrosine kinase [Mer variant] 
F8WED1 Tyrosine-protein kinase Mer 
F0UY65 Tyrosine-protein kinase receptor [Alk] 
A9YLN4 Tyrosine-protein kinase receptor [CD4-ROS1 fusion] 
A9YLN5 Tyrosine-protein kinase receptor [SLC34A2-ROS1 fusion] 
A8K3Z4 Tyrosine-protein kinase receptor [trkA] 
Q548C2 Tyrosine-protein kinase receptor [trkB] 
P35590 Tyrosine-protein kinase receptor Tie-1 
F5H4Q1 Tyrosine-protein kinase receptor TYRO3 
P30530 Tyrosine-protein kinase receptor UFO 
P34925 Tyrosine-protein kinase RYK 
Q6J9G0* Tyrosine-protein kinase STYK1 
A2VCQ3 Tyrosine-protein kinase transmembrane receptor ROR1 
P35916 Vascular endothelial growth factor receptor 3 
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Supplementary Table 3: Satistical analysis of assay data. Statistics were determined for 
interleaved-format plates (each plate contained ten columns for DMSO and ten columns for INH 
with alternating order; also see Materials and Methods). 
Plate Statistics 
Day 1, Plate 1 
 
 
Mean (DMSO) 40756 
SD (DMSO) 3689 
Mean (INH) 1217 
SD (INH) 271 
Z‘  0.70 
Day 1, Plate 2 
 
Mean (DMSO) 42404 
SD (DMSO) 3925 
Mean (INH) 1225 
SD (INH) 269 
Z‘  0.69 
Day 2, Plate 1 
 
Mean (DMSO) 60338 
SD (DMSO) 5068 
Mean (INH) 1632 
SD (INH) 341 
Z‘  0.72 
Day 2, Plate 2 
 
Mean (DMSO) 53434 
SD (DMSO) 4865 
Mean (INH) 1599 
SD (INH) 318 
Z‘  0.70 
  
  
 
Ingles-Prieto et al. 19 
 
References 
1. Grusch, M. et al. EMBO J. 33, 1713-1726 (2014). 
2. Finn, R.D. et al. Nucleic Acids Res. 42, D222-230 (2014). 
3. Krogh, A., Larsson, B., von Heijne, G. & Sonnhammer, E.L. J. Mol. Biol. 305, 567-580 
(2001). 
4. Edgar, R.C. Bioinformatics 26, 2460-2461 (2010). 
